Overall and Line-Specific Impact of Targeted Therapies in Advanced Biliary Tract Cancer After Chemoimmunotherapy Failure

Study limitation reported by the research below: “The benefit of matched targeted therapy was not demonstrated in the third-line setting, suggesting results should not be extrapolated beyond second-line use.”